However, only a small population of patients with unresectable HCC show promising clinical responses to anti-PD-L1 treatment, and many patients do not benefit from anti-PD-L1 treatment or discontinue treatment due to very serious side effects[8]. The gene discussed is CD274; the disease is hepatocellular carcinoma.